This topic strongly stimulated our interest because the evidence suggests that Ang-(1-7) or other Mas agonists might be useful in the development of therapeutic agents to counteract the adverse role of Ang II/AT1R in DN. This evidence concerns the gene AGTR1 and liver dysplastic nodule.